Alphabetical list of MAX2 score. Primary CSF prophylaxis decreases MAX 2 by 0.06, unless included mandatorily in the regimen design. Doses are in mg/m2 unless specified otherwise.
If the MAX2 of the chemotherapy is <0.20 and the patient had no 1st cycle neutropenia, then the risk of G4 neutropenia in the subsequent cycles is <5%, and the risk of febrile neutropenia <1.5%. Ref: Janssen-Heijnen et al., Crit Rev Oncol Hematol, e-pub Aug 2, 2010. Pubmed ID: 20685130
|
Regimen |
MAX2 |
|
5FU/LV qw 6/8 (Roswell Park) |
0.183 |
|
5-FU/LV q4-5w (Mayo) |
0.166 |
|
5FU/LV qw 6/8 (Roswell Park)+ bevacizumab |
0.168 |
|
AC |
0.223 |
|
CAF |
0.291 |
|
Capecitabine 2500 |
0.121 |
|
Carboplatin/gemcitabine AUC 4-6/1g q3w |
0.135 |
|
Carboplatin/pemetrexed |
0.089 |
|
Carboplatin/paclitaxel (6/200) |
0.149 |
|
Carboplatin/docetaxel (5-6/75) |
0.249 |
|
CHOP |
0.341 |
|
Cisplatin/docetaxel 75/75 |
0.251 |
|
Cisplatin/etoposide 75-80/100 q3w |
0.337 |
|
Cisplatin/gemcitabine d1,8,15 q4w |
0.285 |
|
Cisplatin/gemcitabine d1,8 q3w |
0.117 |
|
Cisplatin/irinotecan q3w |
0.262 |
|
Cisplatin/pemetrexed |
0.079 |
|
Cisplatin/paclitaxel 75/135-24h |
0.477 |
|
CMF po |
0.207 |
|
Dacarbazine |
0.064 |
|
Docetaxel 75 q3w |
0.253 |
|
Docetaxel 100 q3w |
0.398 |
|
Docetaxel weekly |
0.041 |
|
Doxorubicine 60 |
0.181 |
|
Doxorubicine 75 |
0.408 |
|
ECF |
0.149 |
|
Fludarabine |
0.138 |
|
FOLFIRI |
0.075 |
|
FOLFOX 4 |
0.119 |
|
FOLFOX 6 |
0.172 |
|
Gemcitabine 1g 3/4 weeks |
0.077 |
|
Gemcitabine 1.25g 3/4 weeks |
0.076 |
|
Gemcitabine 1g 7/8 then 3/4 weeks |
0.11 |
|
Gemcitabine FDR 1.5g 3/4 weeks |
0.193 |
|
Gemcitabine/irinotecan |
0.125 |
|
Gemcitabine/pemetrexed d8 |
0.239 |
|
Irinotecan q3w |
0.226 |
|
PEG doxorubicin (Doxil) 50 q4w |
0.089 |
|
Pemetrexed |
0.042 |
|
Paclitaxel 175 q3w |
0.3 |
|
Paclitaxel 200 q3w |
0.239 |
|
Paclitaxel 80 weekly |
0.08 |
|
Topotecan IV |
0.346 |
|
Topotecan oral |
0.221 |
|
Topotecan weekly |
0.124 |
|
XELOX |
0.134 |
